Skip to content
PubMed This is a summary of 12 peer-reviewed journal articles Updated
Neurology

Classic vs. Atypical PKAN: Understanding Your Subtype

At a Glance

Classic PKAN usually begins in early childhood and progresses faster, while atypical PKAN often starts in the teens or adulthood and changes more slowly, with varied movement, speech, and behavior changes. PANK2 gene changes can offer clues but cannot reliably predict one person’s course.

While every person with Pantothenate Kinase-Associated Neurodegeneration (PKAN) has a unique experience, doctors generally group the condition into two main categories: classic and atypical. These labels help the medical team predict the likely speed of progression and decide which symptoms—such as movement or psychiatric changes—need the most attention [1][2].

It is important to remember that these are broad categories. Your or your child’s journey may not fit perfectly into one box, and the subtype label is a starting point for conversation, not a fixed guarantee of the future [1][3].

Classic PKAN: Early Childhood Onset

The classic form of PKAN is the most common presentation. It usually begins in early childhood, often before the age of 6, though the general clinical cutoff is often set at age 10 [4][2].

  • Initial Signs: The first sign is often a change in how a child walks (gait disturbance). You might notice “clumsiness,” frequent tripping, or difficulty keeping up with peers [4].
  • Movement Progression: Movement challenges usually progress rapidly. Within a few years, dystonia—involuntary muscle contractions that cause twisting or repetitive movements—often spreads from the legs to the rest of the body [4][1].
  • Communication and Nutrition: Children with classic PKAN are more likely to experience early difficulties with speech (dysarthria) and swallowing (dysphagia) [1][4].
  • Vision: This subtype is more frequently associated with pigmentary retinopathy, a gradual loss of vision caused by changes in the back of the eye [1][5].
  • Timeline Notes: On average in historical group data, children with classic PKAN may require a wheelchair for mobility within 5 to 10 years after the first symptoms appear. However, this varies significantly between individuals and should not be interpreted as an absolute deadline [4][2].

Atypical PKAN: Later Onset and Varied Symptoms

The atypical form of PKAN usually begins later, often in the second decade of life (the teens), but it can also appear in early adulthood or overlap the age 10 boundary [1][2].

  • Diverse Presentation: While classic PKAN follows a fairly predictable path, atypical PKAN is much more varied. It might start with subtle speech changes, “freezing” while walking (parkinsonism), or even psychiatric symptoms rather than obvious motor problems [6][7].
  • Neuropsychiatric Features: About one-third of people with atypical PKAN experience behavioral or psychiatric changes. These can include impulsivity, difficulty with planning (executive dysfunction), or obsessive thoughts [7][8].
  • Slower Progression: Generally, the atypical form progresses more slowly than the classic form. Many individuals maintain the ability to walk and care for themselves for many decades [1][9].
  • “Step-wise” Changes: Anecdotally, some families report that atypical PKAN doesn’t decline steadily; instead, it may have a period of rapid change followed by a long, stable plateau where symptoms do not get worse for many years, though this is not a dependable forecast [10].

Comparison of Clinical Subtypes

Feature Classic PKAN Atypical PKAN
Typical Age of Onset Before age 10 (often 3–6 years) [2] After age 10 (teens or early 20s) [2]
Progression Speed Rapid [1] Slower and more varied [1]
Primary Symptoms Gait difficulty, leg dystonia [4] Speech changes, psychiatric symptoms, parkinsonism [7]
Vision Problems Can be common (Retinopathy) [1] Less frequent [1]
Loss of Walking Often within 10 years of onset [4] May be maintained for decades [9]

Why Variations Happen

You may wonder why individuals with the same diagnosis can have such different experiences. Part of the answer lies in the specific PANK2 gene mutation.

  • The Type of Mutation: Research has looked at whether “null” mutations—where the gene produces no working enzyme at all—are usually linked to the earlier, more rapid classic form [2][11]. Mutations that allow for a small amount of working enzyme are often seen in the atypical form [2]. However, variant type does not perfectly or reliably forecast onset, severity, or rate of progression.
  • Individual Differences: Even siblings with the exact same genetic mutation can have different ages of onset or different symptoms [3][12]. This suggests that other genes or environmental factors also play a role in how the disease behaves.

Understanding your subtype is a tool to help you anticipate needs, but your own history and current symptoms remain the most important guide for care.

Common questions in this guide

What is the difference between classic and atypical PKAN?
Classic PKAN usually begins in early childhood and tends to progress more quickly, with gait problems and dystonia often appearing early. Atypical PKAN usually begins after age 10, often in the teens or early adulthood, and has a slower, more varied course that may include speech, walking, or psychiatric changes. These are broad categories, not fixed predictions.
When does classic PKAN usually begin, and what are the first signs?
Classic PKAN often begins before age 6, although clinicians commonly use age 10 as a broad cutoff. A change in walking, such as clumsiness or frequent tripping, is often the first sign, followed by movement problems such as dystonia. Children may also develop early speech or swallowing difficulties.
What symptoms can atypical PKAN cause?
Atypical PKAN may begin with subtle speech changes, freezing while walking, or parkinsonism rather than obvious motor problems. Some people develop behavioral or psychiatric changes such as impulsivity, difficulty planning, or obsessive thoughts. Symptoms and their order vary widely.
Does a PANK2 mutation determine which PKAN subtype someone has?
Some PANK2 variants that produce no working enzyme have been associated with classic PKAN, while variants allowing some enzyme activity are often seen in atypical PKAN. However, the mutation type cannot reliably predict age of onset, severity, or progression. Even siblings with the same variant may have different experiences.
How quickly does PKAN progress, and when might walking be lost?
Classic PKAN generally progresses faster, and historical group data suggest some children may need a wheelchair within 5 to 10 years after symptoms begin. Atypical PKAN often progresses more slowly, and many people continue walking and caring for themselves for decades. These timeframes vary and are not deadlines for any individual.
What should be monitored as PKAN progresses?
Monitoring may focus on movement, speech, swallowing, vision, and changes in behavior or planning. Tracking when symptoms begin and how quickly daily abilities change can help the care team adjust support, including school or workplace accommodations. The appropriate monitoring schedule depends on the individual’s symptoms.

Questions For You

Answer a question to get research tailored to you. Your answers are private.

Get notified when new evidence is published on Pantothenate kinase-associated neurodegeneration.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Based on the age of onset and the first symptoms, does this case align more closely with classic or atypical PKAN?
  2. 2.How often should we re-evaluate motor, speech, and swallowing functions to track the rate of progression?
  3. 3.What are the specific risks regarding swallowing or vision based on current symptoms?
  4. 4.Are the behavioral or emotional changes we are seeing a recognized part of the condition, and how can we manage them?
  5. 5.Who can help us map out school or workplace accommodations as symptoms change?

References

References (12)
  1. 1

    Patient and caregiver experiences with pantothenate kinase-associated neurodegeneration (PKAN): results from a patient community survey.

    Klopstock T, Mercimek-Andrews S, Jurecka A, et al.

    Orphanet journal of rare diseases 2023; (18(1)):257 doi:10.1186/s13023-023-02869-1.

    PMID: 37653408
  2. 2

    Natural history and genotype-phenotype correlation of pantothenate kinase-associated neurodegeneration.

    Chang X, Zhang J, Jiang Y, et al.

    CNS neuroscience & therapeutics 2020; (26(7)):754-761 doi:10.1111/cns.13294.

    PMID: 32043823
  3. 3

    A novel homozygous variation in the PANK2 gene in two Persian siblings with atypical pantothenate kinase associated neurodegeneration.

    Habibi AH, Razmeh S, Aryani O, et al.

    Neurology international 2019; (11(1)):7959 doi:10.4081/ni.2019.7959.

    PMID: 30996846
  4. 4

    [Phenotypic and genotypic features of twenty children with classic pantothenate kinase-associated neurodegeneration].

    Zhou J, He J, Kou LP, et al.

    Zhonghua er ke za zhi = Chinese journal of pediatrics 2017; (55(9)):678-682 doi:10.3760/cma.j.issn.0578-1310.2017.09.011.

    PMID: 28881514
  5. 5

    Neurodegeneration with brain iron accumulation.

    Gregory A, Hayflick SJ

    Folia neuropathologica 2005; (43(4)):286-96.

    PMID: 16416393
  6. 6

    Clinical Heterogeneity of Atypical Pantothenate Kinase-Associated Neurodegeneration in Koreans.

    Lee JH, Park J, Ryu HS, et al.

    Journal of movement disorders 2016; (9(1)):20-7 doi:10.14802/jmd.15058.

    PMID: 26828213
  7. 7

    All that glitters is not gold: When motor and vocal tics in a child do not match Tourette syndrome: A case report.

    da Costa RQM, Marrocos RP, Leite MAA, Porto FHG

    Dementia & neuropsychologia 2016; (10(3)):251-253 doi:10.1590/S1980-5764-2016DN1003014.

    PMID: 29213464
  8. 8

    Neuropsychological functions and psychiatric symptoms in late-onset manifestation of pantothenate kinase-associated neurodegeneration: a clinical case report.

    Palmeri R, Lo Buono V, Berenati M, et al.

    The International journal of neuroscience 2020; (130(5)):490-492 doi:10.1080/00207454.2019.1694924.

    PMID: 31738088
  9. 9

    Estimation of Ambulation and Survival in Neurodegeneration with Brain Iron Accumulation Disorders.

    Amini E, Rohani M, Lang AE, et al.

    Movement disorders clinical practice 2024; (11(1)):53-62 doi:10.1002/mdc3.13933.

    PMID: 38291840
  10. 10

    Pattern of disease progression in atypical form of pantothenate-kinase-associated neurodegeneration (PKAN) - Prospective study.

    Tomić A, Petrović I, Svetel M, et al.

    Parkinsonism & related disorders 2015; (21(5)):521-4.

    PMID: 25724846
  11. 11

    Novel PANK2 Mutations in Patients With Pantothenate Kinase-Associated Neurodegeneration and the Genotype-Phenotype Correlation.

    Li WB, Shen NX, Zhang C, et al.

    Frontiers in aging neuroscience 2022; (14()):848919 doi:10.3389/fnagi.2022.848919.

    PMID: 35462688
  12. 12

    Rare PANK2 variants and pantothenate-kinase-associated neurodegeneration in the Dominican Republic.

    Vardarajan BN, Roa PS, Kim CY, et al.

    Brain communications 2025; (7(4)):fcaf286 doi:10.1093/braincomms/fcaf286.

    PMID: 40799282

This page explains classic and atypical PKAN for informational purposes only and does not constitute medical advice. A neurologist and care team can interpret your or your child’s symptoms and discuss appropriate monitoring.